U.S. federal trademark · Serial No. 85037493 · Reg. No. 3952824
Treatment of obesity, lipid disorders, metabolic disorders, cardiovascular diseases, diseases of the immune system, age-related diseases, cancer, and diseases caused by diabetes such as diabetic neuropathy, obesity, dyslipidemia, hypercholestermia, and hypertension through the therapy of changing the aberrant phase relationships of specific pacemaker biological clock circadian peak neuronal outputs, e.g., messaging or transmission, within the central nervous system
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.